Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
- Resource Type
- Source
- REGAIN Study Group 2019, ' Long-term safety and efficacy of eculizumab in generalized myasthenia gravis ', Muscle & Nerve, vol. 60, no. 1, pp. 14-24 . https://doi.org/10.1002/mus.26447
MUSCLE & NERVE
Muppidi, S, Utsugisawa, K, Benatar, M, Murai, H, Barohn, R J, Illa, I, Jacob, S, Vissing, J, Burns, T M, Kissel, J T, Nowak, R J, Andersen, H, Casasnovas, C, De Bleecker, J L, Vu, T H, Mantegazza, R, O'Brien, F L, Wang, J J, Fujita, K P, Howard, J F & REGAIN Study Group 2019, ' Long-term safety and efficacy of eculizumab in generalized myasthenia gravis ', Muscle & Nerve, vol. 60, no. 1, pp. 14-24 . https://doi.org/10.1002/mus.26447
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Muscle & nerve, 60(1), 14-24. John Wiley and Sons Inc. - Subject
0301 basic medicine Male Pediatrics Exacerbation Physiology Heart Diseases/chemically induced Myasthenia Gravis/drug therapy 030105 genetics & heredity THERAPY DOUBLE-BLIND 0302 clinical medicine Quality of life Monoclonal Activities of Daily Living Medicine and Health Sciences Functional ability Longitudinal Studies Humanized Angioedema/chemically induced MG-ADL QMG Eculizumab Middle Aged myasthenia gravi 3. Good health Treatment Outcome Antibodies, Monoclonal, Humanized/therapeutic use Meningococcal Infections/epidemiology Disease Progression Female eculizumab Life Sciences & Biomedicine COMPLEMENT INHIBITOR ECULIZUMAB medicine.drug Adult medicine.medical_specialty MG-QOL15 Heart Diseases Clinical Neurology Meningococcal Vaccines Antibodies, Monoclonal, Humanized Placebo Antibodies ACETYLCHOLINE-RECEPTOR Complement Inactivating Agents/therapeutic use 03 medical and health sciences Cellular and Molecular Neuroscience Refractory Physiology (medical) Injection Site Reaction/epidemiology Myasthenia Gravis medicine Aspergillosis Aspergillosis/epidemiology Humans Muscle Strength Angioedema myasthenia gravis Science & Technology business.industry MGC Neurosciences Meningococcal Vaccines/therapeutic use medicine.disease Interim analysis Complement Inactivating Agents Injection Site Reaction Meningococcal Infections Quality of Life Myasthenia gravis ANTIBODY Neurosciences & Neurology Neurology (clinical) business 030217 neurology & neurosurgery - Language
- English
- ISSN
- 0148-639X
1097-4598